Immunomedics, Inc. Develops Dendritic-Cell Vaccine Technology for Lymphomas and Leukemias

23 Oct 2013

·www.biospace.com

VaccineCollaborateAntibody

MORRIS PLAINS, N.J., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the issuance of U.S. patent no. 8,562,988 to its majority-owned subsidiary, IBC Pharmaceuticals, Inc. (IBC), for "Novel Strategies for Improved Cancer Vaccines." Help employers find you! Check out all the jobs and post your resume.

Organizations

IBC Pharmaceuticals, Inc.

Immunomedics, Inc.

Indications

LymphomaLeukemiaNeoplasms

Targets

Drugs

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.